Pipeline
Empowering Access & Innovation in Biologics
At GeNext Genomics, our pipeline reflects our dual commitment:
- To expand access through high-quality, affordable biosimilars, and
- To innovate with novel therapeutic antibodies for unmet or emerging medical needs.
With a strong foundation in antibody discovery, clone development, expression optimization, and early-stage analytics, our development programs align with international regulatory expectations and are powered by our proprietary platforms.
Explore our development focus areas below:
Biosimilars
Novel Therapeutics
Affordable Innovation Through Equivalence
At GeNext Genomics, we are driving forward a focused biosimilar portfolio targeting autoimmune, inflammatory, and oncology indications. Our biosimilar programs are internally coded, actively monitored, and follow a stringent quality-controlled process from clone development to IND-enabling stages.
Biosimilars Pipeline
| Sr.no | GNG Code | Molecule | Indication | Development Stage |
|---|---|---|---|---|
| 01 | GNG-BIO-01 | Golimumab | Rheumatoid Arthritis | Pre-clinical |
| 02 | GNG-BIO-02 | Dostarlimab | Endometrial cancer (dMMR/MSI-H) | Clone optimization |
| 03 | GNG-BIO-03 | Pembrolizumab | Non-small cell lung cancer (NSCLC), Melanoma | Clone Screening |
| 04 | GNG-BIO-04 | Nivolumab | Renal cell carcinoma, Melanoma | Discovery |
| 05 | GNG-BIO-05 | Daratumumab | Multiple myeloma | Discovery |
| # | GNG Code | Molecule | Disease Indication | CLD | RCB | PD | Pre-clinical |
|---|---|---|---|---|---|---|---|
| 01 | BSP001 | Golimumab Anti-TNF monoclonal antibody Autoimmune / Inflammatory |
Rheumatoid arthritis, Psoriasis & Ulcerative Colitis | ||||
| 02 | BSP002 | Dostarlimab Anti-PD-1 checkpoint antibody Oncology |
Colorectal & Rectal Cancer | — | |||
| 03 | BSP003 | Pembrolizumab Anti-PD-1 checkpoint inhibitor Oncology |
Non-small cell lung carcinoma, Head and neck cancer | — | |||
| 04 | BSP004 | Nivolumab Anti-PD-1 checkpoint inhibitor Immunotherapy |
Non-small cell lung carcinoma, Head and neck cancer | — | — | ||
| 05 | BSP005 | Daratumumab Anti-CD38 monoclonal antibody Hematology / Oncology |
Multiple Myeloma | — | — | ||
| 06 | BSP006 | Trastuzumab Anti-HER2 monoclonal antibody Oncology |
HER2-positive breast cancer, HER2-positive gastric cancer | — | — | — | |
| 07 | BSP007 | Dupilumab Anti-IL-4Rα monoclonal antibody Immunology |
Atopic dermatitis, Asthma | — | — | — | |
| 08 | BSP008 | Denosumab Anti-RANK-L monoclonal antibody Oncology / Bone |
Osteoporosis, Bone loss due to cancer therapy | — | — |
Our Development Capabilities
Proprietary CHO/HEK clone development platforms
High-yield expression using UCOE-based vectors
Comparability studies aligned with EMA/FDA biosimilar guidelines
In-house analytics: SPR/BLI, ELISA, SDS-PAGE, SEC-HPLC
Full process development readiness (USP → DSP)
Partner with Us
Whether you are a biotech innovator, CDMO, or a pharmaceutical company looking to expand your biosimilar portfolio, GNG offers flexible engagement models, co-development, and technology transfer pathways.
Reach Out to Collaborate on- info@genextgenomics.com
Science-Driven Solutions for Tomorrow’s Threats
Beyond biosimilars, GeNext Genomics is also innovating on the frontier of immunotherapy and infectious diseases. Our novel antibody programs leverage our proprietary HIND Phage Display Library for rapid discovery of high-affinity, fully human antibodies.
Neutralizing Antibody
Biodefense
(Identified from
HIND® Library)
Affinity maturation
Program Summary
We are advancing a neutralizing antibody program targeted toward a critical pathogen associated with biological risk. This initiative is part of our preparedness strategy and remains under restricted disclosure due to its national importance and public health sensitivity.
Further updates will be available as the program reaches collaboration-ready milestones.
Confidential & Collaborative
Due to the sensitive nature of this development, detailed data is only available under CDA/NDA frameworks. For institutional or strategic partners interested in biodefense therapeutics or rare infectious disease targets:
Contact Our Scientific on – info@genextgenomics.com
Summary
| Sr.no | Pipeline Type | No. of Active Programs | Development Range |
|---|---|---|---|
| 01 | Biosimilars | 8 | Discovery to IND-enabling |
| 02 | Novel Therapeutics | 2 (Restricted Disclosure) | Discovery Phase |
Ready to Connect?
✉ Write to us at: info@genextgenomics.com
🌐 Visit: www.genextgenomics.com/contact-us
Connect with
GeNext Genomics
discuss your project requirements and receive a
customized quote.
GET IN TOUCH WITH US